A Phase 3 interventional study of Cagrilintide and Semaglutide in Type 2 Diabetes Mellitus, sponsored by Novo Nordisk A/S. Completed at 405 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.
Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 2 that started in 2023, is one of 10 in phase 3, and was the 3rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Brazil and 7 more countries
Ages 10–18
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2023.
This study's enrollment of 2,734 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 274 across the 15 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 9th largest by enrollment of the 428 interventional ones that give a count, is one of 15 that started in 2023, is one of 187 in phase 3, and was the 585th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
2 of the studies testing cagrilintide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once-weekly subcutaneous (s.c) injections of cagrilintide dose 1 and semaglutide dose 1 for 68 weeks.
Drug: Cagrilintide · Drug: Semaglutide
Participants will receive once-weekly s.c injections of cagrilintide dose 2 and semaglutide dose 2 for 68 weeks.
Drug: Cagrilintide · Drug: Semaglutide
Participants will receive once-weekly s.c injection of semaglutide dose 1 for 68 weeks.
Drug: Semaglutide
Participants will receive once-weekly s.c injection of semaglutide dose 2 for 68 weeks.
Drug: Semaglutide
Participants will receive once-weekly s.c injection of cagrilintide dose 1 for 68 weeks.
Drug: Cagrilintide
Participants will receive once-weekly s.c injection of placebo matched to cagrilintide dose 1 and semaglutide dose 1 for 68 weeks.
Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Participants will receive once-weekly s.c injection of placebo matched to cagrilintide dose 2 and semaglutide dose 2 for 68 weeks.
Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached.
Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
Participants will receive placebo matched to cagrilintide subcutaneously.
Participants will receive placebo matched to semaglutide subcutaneously.
CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)
Measured in percentage-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus cagrilintide: Change in HbA1c
Measured in percentage-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus cagrilintide: Relative change in body weight
Measured in percentage.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema (dose 1) versus semaglutide (dose 2): Change in HbA1c
Measured in percentage-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Relative change in body weight
Measured in percentage.
Time frame: From baseline (week 0) to end of treatment (week 68)
Cagrilintide versus placebo: Change in HbA1c
Measured in percentage-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
Cagrilintide versus placebo: Relative change in body weight
Measured in percentage.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Achievement of greater than or equal to (>=) 10 percent (%) weight reduction
Measured as count of participants.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Achievement of >= 15 % weight reduction
Measured as count of participants.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Achievement of >= 20 % weight reduction
Measured as count of participants.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema (pooled doses) versus semaglutide (pooled doses): Continuous Glucose Monitoring (CGM) - Change in Time in Range (TIR) 3.9-10.0 millimoles per litre (mmol/L) (70-180 milligrams per decilitre [mg/dL])
Measured in percentage-points.
Time frame: From baseline (week -3) to end of treatment (week 68)
CagriSema versus semaglutide: CGM - Change in time in Tight Target Range (TITR) 3.9-7.8 (mmol/L) (70-140 mg/dL)
Measured in percentage-points.
Time frame: From baseline (week -3) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Systolic Blood Pressure (SBP)
Measured in millimeters of mercury (mmHg).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in triglycerides
Measured as ratio of triglycerides.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in non-High Density Lipoprotein (HDL) cholesterols
Measured as ratio of non-HDL cholesterol.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: CGM - Change in Time In Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Measured in percentage-points.
Time frame: From baseline (week -3) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in high sensitivity C-Reactive Protein (hsCRP)
Measured as ratio of hsCRP.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Fasting Plasma Glucose (FPG)
Measured in mmol/L.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Achievement of HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Measured as count of participants.
Time frame: At end of treatment (week 68)
CagriSema versus semaglutide: Achievement of HbA1c target values of less than or equal to (≤)6.5% (≤48 mmol/mol)
Measured as count of participants.
Time frame: At end of treatment (week 68)
CagriSema versus semaglutide: CGM - Change in time above range, >10.0 mmol/L (>180 mg/dL)
Measured in percentage-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: CGM - Change in time above range, >13.9 mmol/L (>250 mg/dL)
Measured in percentage-points.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: CGM - Within-day glycaemic variability (% coefficient of variation [CV])
Measured in percentage.
Time frame: At end of treatment (week 68)
CagriSema versus semaglutide: Achievement of ≥ 5 % weight reduction
Measured as count of participants.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in waist circumference
Measured in centimetre.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Diastolic Blood Pressure (DBP)
Measured in mmHg.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in total cholesterol
Measured as ratio of total cholesterol.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in HDL cholesterol
Measured as ratio of HDL cholesterol.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in low-density lipoprotein (LDL) cholesterol
Measured as ratio of LDL cholesterol.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in very low-density lipoprotein (VLDL) cholesterol
Measured as ratio of VLDL.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Ratio to baseline in free fatty acids
Measured as ratio of free fatty acids.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Short Form (SF)-36v score- Physical component summary score
SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Physical component summary score range from 6.1 to 79.7, with higher scores indicating better functional health and well-being.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in SF-36v2 score- Mental component summary score
SF-36v2 measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and an standard deviation of 10. Mental component summary score range from -3.8 to 78.7, with higher scores indicating better functional health and well-being.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
DTSQc measures treatment satisfaction and diabetes-specific quality of life (QoL). The measure consists of 8 items yielding 1 global score and 2 single item scores. Total treatment satisfaction scores range from 0-36, with higher scores indicating greater satisfaction; the perceived frequency of hyperglycemia/hypoglycemia items are scored separately, with lower scores indicating better perceived blood glucose control.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide: Change in Treatment Related Impact Measure for Diabetes (TRIM-D) score
TRIM-D measures impact of diabetes treatment. The measure consists of 28 items yielding 5 domain scores and a total score. The scores were transformed to a 0-100 scale with higher scores indicating a better health state.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide, placebo and cagrilintide: Number of treatment emergent adverse events (TEAEs)
Measured as count of events.
Time frame: From baseline (week 0) to end of study (week 75)
CagriSema versus semaglutide: Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL), confirmed by BG meter)
Measured as count of episodes.
Time frame: From baseline (week 0) to end of study (week 75)
CagriSema versus semaglutide: Number of severe hypoglycaemic episodes (level 3)
Measured as count of episodes. Hypoglycaemia episodes (level 3) are the episodes associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold.
Time frame: From baseline (week 0) to end of study (week 75)
Showing the first 100 of 405 sites across 32 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Sep 2023 to primary completion in Nov 2025, 25 months.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide